Safety Reporting

Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.

 

4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.

The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.

The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.

4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.

4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).

Clinical Research News

Queda de cabelo em mulheres: gel PP405 busca reativar folículos adormecidos
EloraTZP mostrou mais perda de peso que a tirzepatida — e mais interrupções do tratamento
Ler sem óculos? FDA amplia aprovação do colírio Ryzumvi
Could Ultrasound Reduce Chronic Migraine Days? A New Trial Targets the Brain
De uma vacina contra o melanoma à insulina semanal: 9 avanços médicos
Alzheimer: ultrassom durante o sono pode ajudar o cérebro a eliminar beta-amiloide?
A vacina contra o herpes-zóster também pode proteger contra infarto e AVC?

Próximos ensaios clínicos

Clinical Research Jobs

More jobs

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

Se inscrever